instruction stringlengths 1.05k 19.6k | prompt stringclasses 1
value | output stringlengths 45 233 |
|---|---|---|
{'Official Title': 'A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subje... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1 status. Exclude: Subjects with epidermal growth factor receptor (EGFR) sensitizing mutations (identified in exons 19, 20, or 21),'} |
{'Official Title': 'A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subje... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1 status. Exclude: Subjects with epidermal growth factor receptor (EGFR) sensitizing mutations (identified in exons 19, 20, or 21),'} |
{'Official Title': 'A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression', 'Brief Summary': 'The main objective ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: Fibroblast growth factor receptor 2b (FGFR2b) ≥10% 2+/3+ tumor cell staining Exclude: Known human epidermal growth factor receptor 2 (HER2) positive'} |
{'Official Title': 'A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression', 'Brief Summary': 'The main objective ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: Fibroblast growth factor receptor 2b (FGFR2b) ≥10% 2+/3+ tumor cell staining Exclude: Known human epidermal growth factor receptor 2 (HER2) positive'} |
{'Official Title': 'A Open-label, Single-arm, Single-center, Phase II Clinical Study of Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer', 'Brief Summary': 'This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: BRCA1/2 germline mutations'} |
{'Official Title': 'A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer', 'Brief Summary': 'The purpose of this study is to evaluate relatlimab in combination wit... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: evaluable PD-L1 expression'} |
{'Official Title': 'A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer', 'Brief Summary': 'The purpose of this study is to evaluate relatlimab in combination wit... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: evaluable PD-L1 expression'} |
{'Official Title': 'A Phase II, Prospective, Single-center, Randomized, Controlled Study to Investigate the Efficacy and Safety of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Plat... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: Wild type EGFR '} |
{'Official Title': 'A Phase II, Prospective, Single-center, Randomized, Controlled Study to Investigate the Efficacy and Safety of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Plat... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: Wild type EGFR '} |
{'Official Title': 'A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Versus Tislelizumab Plus Placebo as Second-Line Treatment in Patients With PD-L1 Tumor Area Positi... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1 TAP ≥ 10% in tumor tissues'} |
{'Official Title': 'A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Versus Tislelizumab Plus Placebo as Second-Line Treatment in Patients With PD-L1 Tumor Area Positi... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: PD-L1 TAP ≥ 10% in tumor tissues'} |
{'Official Title': 'A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)', 'Brief Summary': 'The purpose of t... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'BRCA Non-mutated'} |
{'Official Title': 'A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)', 'Brief Summary': 'The purpose of t... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'BRCA Non-mutated'} |
{'Official Title': 'A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)', 'Brief Summary': 'The purpose of t... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'BRCA Non-mutated'} |
{'Official Title': 'APK Mutant: A Single Arm Phase II Study of Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer', 'Brief Summary': 'A prospective, multi-center, phase II study of 21 patients to evaluate the efficacy of the EGFR inhibitor, Cetuximab in patients w... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: Mutant APC, TP53 and KRAS genes, RAS mutations are allowed (KRAS, NRAS, HRAS). Exlcude: wild type KRAS'} |
{'Official Title': 'A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of TQB3454 Tablets in the Treatment of Advanced Biliary Tract Cancer With Isocitrate Dehydrogenase 1 (IDH1) Mutation. ', 'Brief Summary': 'This study used a randomized, controlled, double-... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'IDH1 Mutated'} |
{'Official Title': 'A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of TQB3454 Tablets in the Treatment of Advanced Biliary Tract Cancer With Isocitrate Dehydrogenase 1 (IDH1) Mutation. ', 'Brief Summary': 'This study used a randomized, controlled, double-... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'IDH1 Mutated'} |
{'Official Title': 'A Placebo-Controlled, Single (Participant) Blind Trial to Evaluate the Safety, Tolerability, and Early Immunogenicity of Peptide-Pulsed Dendritic Cell Vaccination With Nivolumab and Ipilimumab in Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-Mutant ', 'Brief Summary': "This phase I... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'H3 G34 Mutant '} |
{'Official Title': 'A Placebo-Controlled, Single (Participant) Blind Trial to Evaluate the Safety, Tolerability, and Early Immunogenicity of Peptide-Pulsed Dendritic Cell Vaccination With Nivolumab and Ipilimumab in Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-Mutant ', 'Brief Summary': "This phase I... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'H3 G34 Mutant '} |
{'Official Title': 'A Placebo-Controlled, Single (Participant) Blind Trial to Evaluate the Safety, Tolerability, and Early Immunogenicity of Peptide-Pulsed Dendritic Cell Vaccination With Nivolumab and Ipilimumab in Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-Mutant ', 'Brief Summary': "This phase I... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'H3 G34 Mutant '} |
{'Official Title': 'A Placebo-Controlled, Single (Participant) Blind Trial to Evaluate the Safety, Tolerability, and Early Immunogenicity of Peptide-Pulsed Dendritic Cell Vaccination With Nivolumab and Ipilimumab in Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-Mutant ', 'Brief Summary': "This phase I... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'H3 G34 Mutant '} |
{'Official Title': 'A Placebo-Controlled, Single (Participant) Blind Trial to Evaluate the Safety, Tolerability, and Early Immunogenicity of Peptide-Pulsed Dendritic Cell Vaccination With Nivolumab and Ipilimumab in Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-Mutant ', 'Brief Summary': "This phase I... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'H3 G34 Mutant '} |
{'Official Title': 'A Placebo-Controlled, Single (Participant) Blind Trial to Evaluate the Safety, Tolerability, and Early Immunogenicity of Peptide-Pulsed Dendritic Cell Vaccination With Nivolumab and Ipilimumab in Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-Mutant ', 'Brief Summary': "This phase I... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'H3 G34 Mutant '} |
{'Official Title': 'A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) ', 'Brief Summary': 'A randomised phase III, double-blind, placebo-controlled trial with 2:1 (regorafenib : placebo) ', 'Condition': 'Gastro-Oesophageal Cancer ', 'Deta... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-positive participants who have received trastuzumab'} |
{'Official Title': 'A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) ', 'Brief Summary': 'A randomised phase III, double-blind, placebo-controlled trial with 2:1 (regorafenib : placebo) ', 'Condition': 'Gastro-Oesophageal Cancer ', 'Deta... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: HER2-positive participants who have received trastuzumab'} |
{'Official Title': 'Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group', 'Brief Summary': 'The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 m... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'BRAF V600E/K mutation-positive'} |
{'Official Title': 'Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group', 'Brief Summary': 'The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 m... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'BRAF V600E/K mutation-positive'} |
{'Official Title': 'A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer', 'Brief Summary': 'This is a global, randomized, double-blind, ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'RAS, BRAF, MSI, MMR'} |
{'Official Title': 'A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer', 'Brief Summary': 'This is a global, randomized, double-blind, ... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'RAS, BRAF, MSI, MMR'} |
{'Official Title': 'Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers ', 'Brief Summary': 'This phase II trial studies how well binimetinib and palbociclib work compared to TAS-102 in treating patients with KRAS and NRAS mutation positive col... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'KRAS/NRAS Positive '} |
{'Official Title': 'Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers ', 'Brief Summary': 'This phase II trial studies how well binimetinib and palbociclib work compared to TAS-102 in treating patients with KRAS and NRAS mutation positive col... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'KRAS/NRAS Positive '} |
{'Official Title': 'A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1,... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'KRAS p. G12C positive, PD-L1 negative'} |
{'Official Title': 'A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1,... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'KRAS p. G12C positive, PD-L1 negative'} |
{'Official Title': 'A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies', 'Brief Summary': 'This phase II trial studies how well trametinib and docetaxel work in treating patients w... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'KRAS Mutation Positive'} |
{'Official Title': 'Phase IB/II Study of Alpelisib in Combination With Paclitaxel in Patients With PIK3CA-altered Metastatic/Recurrent Gastric Cancer', 'Brief Summary': 'Alpelisib (BYL719) is a PIK3CA-specific inhibitor, which was developed by Novartis (Basel, Switzerland). Our group conducted pre-clinical study of alp... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': ' PIK3CA-altered mutation'} |
{'Official Title': 'An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC', 'Brief Summary': 'The primary objective of the study is to evaluate the efficac... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Epidermal Growth Factor Receptor Mutant'} |
{'Official Title': 'An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC', 'Brief Summary': 'The primary objective of the study is to evaluate the efficac... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Epidermal Growth Factor Receptor Mutant'} |
{'Official Title': 'A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human E... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'HER2 overexpression'} |
{'Official Title': 'A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human E... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'HER2 overexpression'} |
{'Official Title': 'A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human E... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'HER2 overexpression'} |
{'Official Title': 'A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human E... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'HER2 overexpression'} |
{'Official Title': 'A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human E... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'HER2 overexpression'} |
{'Official Title': 'A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human E... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'HER2 overexpression'} |
{'Official Title': 'Randomized Phase IB/II Study of Enzalutamide With and Without Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression ', 'Brief Summary': 'This partially randomized phase IB/II trial studies the side effects and best dose of ribociclib... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'RB Expression Retainng '} |
{'Official Title': 'Randomized Phase IB/II Study of Enzalutamide With and Without Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression ', 'Brief Summary': 'This partially randomized phase IB/II trial studies the side effects and best dose of ribociclib... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'RB Expression Retainng '} |
{'Official Title': 'Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction - A Randomized Phase 2 Trial.', 'Brief Summary': 'Patients with Her2 negative, previously untreated meta... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'HER2-negative'} |
{'Official Title': 'Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction - A Randomized Phase 2 Trial.', 'Brief Summary': 'Patients with Her2 negative, previously untreated meta... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'HER2-negative'} |
{'Official Title': 'Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction - A Randomized Phase 2 Trial.', 'Brief Summary': 'Patients with Her2 negative, previously untreated meta... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'HER2-negative'} |
{'Official Title': 'Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction - A Randomized Phase 2 Trial.', 'Brief Summary': 'Patients with Her2 negative, previously untreated meta... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'HER2-negative'} |
{'Official Title': 'A Multicenter, Randomized,Double-Blind Study of Gefitinib in Combination With Apatinib or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Advanced Non-squamous Non-Small-Cell Lung Cancer', 'Brief Summary': 'The main purpose of this study is to evaluate the safety and efficacy of... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'EGFR Mutation-Positive'} |
{'Official Title': 'A Multicenter, Randomized,Double-Blind Study of Gefitinib in Combination With Apatinib or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Advanced Non-squamous Non-Small-Cell Lung Cancer', 'Brief Summary': 'The main purpose of this study is to evaluate the safety and efficacy of... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'EGFR Mutation-Positive'} |
{'Official Title': 'A Prospective, Pilot Study of First-line Osimertinib With or Without Savolitinib in de Novo MET Positive, EGFR-mutant NSCLCs (FLOWERS) ', 'Brief Summary': 'This is a prospective, pilot, two-arm, randomized, multicenter study exploring the efficacy and safety of osimertinib with or without savolitini... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'MET Positive, EGFRm+'} |
{'Official Title': 'A Prospective, Pilot Study of First-line Osimertinib With or Without Savolitinib in de Novo MET Positive, EGFR-mutant NSCLCs (FLOWERS) ', 'Brief Summary': 'This is a prospective, pilot, two-arm, randomized, multicenter study exploring the efficacy and safety of osimertinib with or without savolitini... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'MET Positive, EGFRm+'} |
{'Official Title': 'A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroesophageal Junction Adenocarcinoma (KEYNOTE-85... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'HER2 negative'} |
{'Official Title': 'A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroesophageal Junction Adenocarcinoma (KEYNOTE-85... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'HER2 negative'} |
{'Official Title': 'A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesop... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'CLDN18.2-Positive, HER2-Negative'} |
{'Official Title': 'A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesop... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'CLDN18.2-Positive, HER2-Negative'} |
{'Official Title': 'A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metasta... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'PD-L1 mutation'} |
{'Official Title': 'A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metasta... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'PD-L1 mutation'} |
{'Official Title': 'A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metasta... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'PD-L1 mutation'} |
{'Official Title': 'A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metasta... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'PD-L1 mutation'} |
{'Official Title': 'A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months', 'Brief Summar... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'BRCA mutational status'} |
{'Official Title': 'A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months', 'Brief Summar... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'BRCA mutational status'} |
{'Official Title': 'A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma', 'Brief Summary': 'This study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by so... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'EZH2 Inhibitor, INI1-Negative'} |
{'Official Title': 'A Phase III, Randomized, Double-Blind Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) ', 'Brief Summary': "This study will evaluate the efficacy and safety o... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: Sensitizing mutation in the EGFR gene progressive during or after treatment/or intolerant to one or more EGFR TKIs, ALK gene rearrangement progressive/intolerant to one or more ALK inhibitors'} |
{'Official Title': 'A Phase III, Randomized, Double-Blind Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) ', 'Brief Summary': "This study will evaluate the efficacy and safety o... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'Include: Sensitizing mutation in the EGFR gene progressive during or after treatment/or intolerant to one or more EGFR TKIs, ALK gene rearrangement progressive/intolerant to one or more ALK inhibitors'} |
{'Official Title': 'A Phase 1B/2 Study of Trastuzumab, Bevacizumab With Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy (TREAZURE) ', 'Brief Summary': 'This is a multicenter, open-label, prospective, phase 2 study of trastuzumab, bevacizumab, and paclitaxel as second-line treatment for patients wit... | Biomarker Extraction Guideline
1. Review the “arms data” and identify the biomarker from the clinical trial arm.
2. Rely only on "arms data" to identify the biomarker. The "arms data" may be incomplete or irrelevant. You should not make assumptions about the "arms data" beyond what is mentioned.
3. Make sure to extr... | {'Arm - Disease - Biomarker': 'HER2-positive'} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.